AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
Zacks.com on MSN

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

AbbVie ABBV has been significantly expanding its presence in the oncology space. What started initially as a two-drug ...

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
The Caledonian-Record

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the ...
MyChesCo on MSN

AstraZeneca wins landmark approval for IMFINZI regimen in early gastric cancer

WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy ...
Kalkine Media

AstraZeneca PLC (NASDAQ:AZN) Nasdaq Futures Science-Driven Growth

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last month, ushering ...
The American Journal of Managed Care

5 Key Oncology FDA Approvals From November

Here are 5 notable oncology FDA approvals from last month: ...
Gastroenterology Advisor

Imfinzi-Based Perioperative Regimen Approved for Gastric/GEJ Cancers

The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.